RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Great Belief International Limited, a BVI investment company, will pay $29 million to acquire SurgiBot, a minimally invasive surgical robot, from TransEnterix of North Carolina. GBIL will manufacture the system in China and work to obtain CFDA approval of SurgiBot. It plans to commercialize the system in China through a Sinopharm subsidiary, while TransEnterix will retain rights to co-promote SurgiBot outside of China. SurgiBot, which has not been approved in any country, is a single-port, robotically enhanced laparoscopic platform for abdominal surgeries.
Source: China Biotoday
